Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn\u27s Disease by Dulai, P. S. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2018
Development and Validation of a Scoring System to
Predict Outcomes of Vedolizumab Treatment in
Patients With Crohn's Disease
P. S. Dulai
B. S. Boland
S. Singh
K. Chaudrey
J. L. Koliani-Pace
See next page for additional authors
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Gastroenterology Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.
Recommended Citation
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Sultan K, Swaminath A, Cao C, . Development
and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. . 2018 Jan 01;
155(3):Article 4513 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/4513. Free full text article.
Authors
P. S. Dulai, B. S. Boland, S. Singh, K. Chaudrey, J. L. Koliani-Pace, G. Kochhar, M. P. Parikh, K. Sultan, A.
Swaminath, C. Cao, and +26 additional authors
This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/4513
Corresponding Author: Parambir S. Dulai, MD, University of California at San Diego, Division of Gastroenterology, 9500 Gilman 
Dr., La Jolla, CA 92093, pdulai@ucsd.edu.
Author Contributions:
1. Study concept and design (PSD, KL, CC)
2. Acquisition of data (PSD, BSB, SS, KC, JLKP, GK, MPP, ES, JH, PC, JM, DW, RH, ACW, LGK, FP, NN, KS, AS, MB, DL, DH)
3. Statistical analysis (PSD, VJ, GYZ, CC)
4. Drafting of manuscript (PSD, CC)
5. Critical revision of the manuscript for important intellectual content (PSD, JTC, JRN, VJ, GYZ, BGF, BS, CAS, EVL, SK, BES, 
JFC, WJS, KL)
6. Study supervision (PSD, KL, CC)
Disclosures:
PSD: Research support, travel support, and honorarium from Takeda, research support from Pfizer, and support from a training grant 
through the National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK007202). BSB: Research support from Takeda, 
and support from CCFA career development award and UCSD KL2 (1KL2TR001444). SS: Research support from Pfizer, and support 
from the American College of Gastroenterology and the Crohn’s and Colitis Foundation. JLKP: Travel support from Takeda. ES: 
Travel support from Takeda. FP: Advisory Board honoraria from Janssen, Ferring and Takeda. NN: Has received grants, speaker fees, 
or advisory board fees from Abbvie, Allergan, Ferring, Janssen, Lupin, and Takeda. KS: Consulting Abbvie. Research Support 
Takeda, Abbvie, Pfizer, Genentech, Celgene. DL: Consulting for Abbive, Salix. DH: Consulting for Abbvie, Takeda, Janssen. VJ: 
Received scientific advisory board fees from AbbVie, Takeda, Janssen and Sandoz; speakers fees from Takeda, Janssen, Ferring. BGF: 
Grant/Research support from AbbVie Inc., Amgen Inc., AstraZeneca/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer-
Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline (GSK), 
Janssen Research & Development LLC., Pfizer Inc., Receptos Inc. / Celgene International, Sanofi, Santarus Inc., Takeda Development 
Center Americas Inc., Tillotts Pharma AG, UCB. Consultant for Abbott/AbbVie, Actogenix, Akros, Albireo Pharma, Allergan, 
Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Avir Pharma, Baxter Healthcare Corp., Biogen Idec, Boehringer-
Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, 
GiCare Pharma, Gilead, Given Imaging Inc., GSK, Inception IBD Inc, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, 
Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestles, Nextbiotix, 
Novonordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Roche/Genentech, Salix Pharma, Serono, 
Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, 
VHsquared Ltd., Warner-Chilcott, Wyeth, Zealand, Zyngenia. Speaker bureau for Abbott/AbbVie, JnJ/Janssen, Lilly, Takeda, Tillotts, 
UCB Pharma. Scientific advisory board Abbott/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., 
Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Ferring, Galapagos, Genentech/Roche, JnJ/
Janssen, Merck, Nestles, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Takeda, Teva, TiGenix, 
Tillotts Pharma AG, UCB Pharma. Board of directors Robarts Clinical Trials. BS: Consulting for Janssen, Salix, Abbvie, Takeda, 
Theravence, Robarts Clinical Trials. CAS: Consulting for Abbvie, Amgen, Celgene, Lilly, Janssen, Sandoz, Pfizer, Prometheus, 
Takeda; speaker for CME activities for Abbvie, Janssen, Pfizer, Takeda; grant support from Abbvie, Janssen, Pfizer and Takeda. EVL: 
Consulting for Janssen, Takeda, AbbVie, UCB, Amgen, Pfizer, Salix, Mesoblast, Eli Lilly, Celgene and CVS Caremark; research 
support from Janssen, Takeda, AbbVie, UCB, Amgen, Pfizer, Genentech, Gilead, Receptos, Celgene, MedImmune, Seres 
Therapeutics, and Robarts Clinical Trials. SK: Consultant to AbbVie, Janssen, Merck, Spherix Health, Pfizer, UCB. Research support 
from UCB. Board member ABIM BES: Consulting and research support from Amgen, Celgene, Janssen, Pfizer, Prometheus 
Laboratories, Takeda; consulting for AbbVie, Akros Pharma, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol-
Myers Squibb, Cowen Services Company, Forest Research Institute, Forward Pharma, Immune Pharmaceuticals, Lilly, Receptos, Salix 
Pharmaceuticals, Shire, Synergy Pharmaceuticals, Theravance Biopharma R&D, TiGenix, TopVert Pharma, UCB Vivelix 
Pharmaceuticals, Target Pharmasolutions, Allergan. JFC: Consultancy/advisory board membership: AbbVie, Amgen, Boehringer-
Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring, Genentech, Janssen and Janssen, Medimmune, Merck & Co., Pfizer, 
Protagonist, Second Genome, Seres, Takeda, Theradiag; Speaker: AbbVie, Ferring, Takeda, Shire; Research support: AbbVie, Janssen 
and Janssen, Genentech, Takeda; Stock options: Intestinal Biotech Development, Genfit. WJS: Personal fees from Kyowa Hakko 
Kirin, Millennium Pharmaceuticals, Celgene Cellular Therapeutics, Santarus, Salix Pharmaceuticals, Catabasis Pharmaceuticals, 
Vertex Pharmaceuticals, Warner Chilcott, Cosmo Pharmaceuticals, Ferring Pharmaceuticals, Sigmoid Biotechnologies, Tillotts 
Pharma, Am Pharma BV, Dr. August Wolff, Avaxia Biologics, Zyngenia, Ironwood Pharmaceuticals, Index Pharmaceuticals, Nestle, 
Lexicon Pharmaceuticals, UCB Pharma, Orexigen, Luitpold Pharmaceuticals, Baxter Healthcare, Ferring Research Institute, Novo 
Nordisk, Mesoblast Inc., Shire, Ardelyx Inc., Actavis, Seattle Genetics, MedImmune (AstraZeneca), Actogenix NV, Lipid 
Therapeutics Gmbh, Eisai, Qu Biologics, Toray Industries Inc,, Teva Pharmaceuticals, Eli Lilly, Chiasma, TiGenix, Adherion 
Therapeutics, Immune Pharmaceuticals, Celgene, Arena Pharmaceuticals, personal fees from Ambrx Inc., Akros Pharma, Vascular 
Biogenics, Theradiag, Forward Pharma, Regeneron, Galapagos, Seres Health, Ritter Pharmaceuticals, Theravance, Palatin, Biogen, 
University of Western Ontario (owner of Robarts Clinical Trials); grants and personal fees from Prometheus Laboratories, AbbVie, 
Gilead Sciences, Boehringer Ingelheim, Amgen, Takeda, Atlantic Pharmaceuticals, Bristol-Myers Squibb Genentech, 
GlaxoSmithKline, Pfizer, Nutrition Science Partners, Receptos, Amgen; grants, personal fees and non-financial support from Janssen; 
grants from Broad Foundation, American College of Gastroenterology, Exact Sciences. KL: Employed by Takeda pharmaceuticals. 
CC: Employed by Takeda pharmaceuticals.
Potential Conflicts of Interest:
All other authors have no disclosures or potential conflicts of interest.
HHS Public Access
Author manuscript
Gastroenterology. Author manuscript; available in PMC 2019 March 15.
Published in final edited form as:
Gastroenterology. 2018 September ; 155(3): 687–695.e10. doi:10.1053/j.gastro.2018.05.039.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Development and Validation of a Scoring System to Predict 
Outcomes of Vedolizumab Treatment in Patients with Crohn’s 
Disease
Parambir S. Dulai1, Brigid S. Boland1, Siddharth Singh1, Khadija Chaudrey2, Jenna L. 
Koliani-Pace3, Gursimran Kochhar4, Malav P. Parikh4, Eugenia Shmidt5, Justin Hartke6, 
Prianka Chilukuri6, Joseph Meserve1, Diana Whitehead3, Robert Hirten7, Adam C. 
Winters5, Leah G. Katta5, Farhad Peerani5,8, Neeraj Narula5,9, Keith Sultan7, Arun 
Swaminath10, Matthew Bohm6, Dana Lukin11, David Hudesman12, John T. Chang1, Jesus 
Rivera-Nieves1, Vipul Jairath13, GY Zou13, Brian G. Feagan13, Bo Shen4, Corey A. Siegel3, 
Edward V. Loftus Jr2, Sunanda Kane2, Bruce E. Sands5, Jean-Frederic Colombel5, William 
J. Sandborn1, Karen Lasch14, and Charlie Cao14
1University of California - San Diego, La Jolla, CA, USA
2Mayo Clinic, Rochester, MN, USA
3Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
4Cleveland Clinic Foundation, Cleveland, OH, USA
5Icahn School of Medicine at Mount Sinai, New York, NY, USA
6Indiana University, Indianapolis, IN, USA
7North Shore University Hospital, Manhasset, NY, USA
8University of Alberta, Edmonton, AB, Canada
9McMaster University Medical Centre, Hamilton, ON, Canada
10Lenox Hill Hospital, New York, NY, USA
11Montefiore Medical Center, New York, NY, USA
12New York University (NYU), New York, NY, USA
13University of Western Ontario, London, ON, Canada
14Takeda Pharmaceuticals USA Inc., Deerfield, IL, USA
Abstract
Background & Aims: As more treatment options for inflammatory bowel diseases become 
available, it is important to identify patients most likely to respond to different therapies. We 
created and validated a scoring system to identify patients with Crohn’s disease (CD) who respond 
to vedolizumab.
Methods: We collected data from GEMINI 2 phase 3 trial of patients with active CD treated with 
vedolizumab for 26 weeks (n=814) and performed logistic regression analysis to identify factors 
associated with clinical, steroid-free, and durable remission (derivation set). We used these data to 
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develop a clinical decision support tool, which we validated using data from 366 participants in a 
separate clinical practice observational cohort of patients with active CD treated with vedolizumab 
for 26 weeks (the VICTORY cohort). We evaluated the ability of this tool to identify patients in 
clinical remission or corticosteroid-free remission, or those with mucosal healing (MH), clinical 
remission with MH, or corticosteroid-free remission with MH after vedolizumab therapy using 
receiver operating characteristic area under the curve (AUC) analyses. The primary outcome was 
to develop and validate a list of factors associated with achieving remission by vedolizumab in 
patients with active CD.
Results: In the derivation analysis, we identified absence of previous treatment with a tumor 
necrosis factor antagonist (+3 points), absence of prior bowel surgery (+2 points), absence of prior 
fistulizing disease (+2 points), baseline level of albumin (+0.4 points per g/L), and baseline 
concentration of C-reactive protein (reduction of 0.5 points for values between 3.0–10.0 mg/L and 
3.0 points for values > 10.0 mg/L) as factors associated with remission. In the validation set, our 
model identified patients in clinical remission with an AUC of 0.67, patients in corticosteroid-free 
remission with an AUC of 0.66, patients with MH with an AUC of 0.72, patients in clinical 
remission with MH with an AUC of 0.73, and patients in corticosteroid-free clinical remission 
with MH with an AUC of 0.75. A cut-off value of 13 points identified patients in clinical 
remission after vedolizumab therapy with 92% sensitivity, patients in corticosteroid-free remission 
with 94% sensitivity, patients with MH with 98% sensitivity, patients in deep remission with 100% 
sensitivity, and patients with corticosteroid-free clinical remission with MH with 100% sensitivity.
Conclusions: We developed and validated a scoring system to identify patients with CD most 
likely to respond to 26 weeks of vedolizumab therapy. Further studies are needed to optimize its 
accuracy in select populations and determine its cost effectiveness.
Graphical Abstract
Keywords
IBD; CD; prediction model; biomarker
INTRODUCTION
Vedolizumab (VDZ), a humanized anti-α4β7 integrin monoclonal antibody that selectively 
targets lymphocyte trafficking to the gut, is currently indicated for the treatment of adult 
patients with moderately to severely active Crohn’s disease (CD) who have failed 
corticosteroids, immunomodulators, or tumor necrosis factor-alpha (TNFα) antagonist 
therapy. In the GEMINI 2 phase III trial, approximately one-third of patients were in clinical 
remission (CREM) or corticosteroid-free clinical remission (CSF-REM) following treatment 
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with VDZ.1 Although these results are clinically important, the GEMINI 2 trial did not 
assess for mucosal healing (MH), and the strict inclusion criteria used may limit the 
generalizability of the results to routine clinical practice.2
Real-world data from multiple jurisdictions are now available for VDZ therapy in CD and 
outcomes are fairly consistent across clinical practice. In the US-based VICTORY 
consortium that evaluated 212 CD patients, CREM, CSF-REM, and deep remission (CREM 
+ MH) were seen in 35%, 34%, and 26% of patients, respectively, by 12 months.3 In real 
world cohorts and in the GEMINI 2 trial, prior exposure to TNFα-antagonists negatively 
affected treatment outcomes.3–5 However, the magnitude of this effect and the influence of 
other clinical factors on treatment outcomes varied across these studies, making it difficult 
for clinicians to interpret their relevance to practice.
Clinical prediction models utilize baseline characteristics to provide an estimate of the value 
of a therapy on treatment outcomes for an individual patient. Furthermore, the 
transformation of these models into decision support tools facilitates their application as a 
component of ‘precision medicine’.6, 7 With the evolving landscape of biologic therapy in 
CD and increasing treatment choice, a validated prognostic tool for treatment outcomes with 
VDZ would be of considerable value.8 We aimed to address this gap by deriving and 
validating a multivariable clinical prediction model within the GEMINI 2 clinical trial 
dataset. To improve the ease with which this prediction model can be used at the ‘bedside’, 
we transformed it into a prognostic clinical decision support tool (CDST) and validated this 
tool in a cohort of CD patients treated with VDZ in routine clinical practice.
METHODS
We developed and validated a multivariable model to predict CREM with VDZ treatment for 
patients with active CD.1, 9, 10 We further assessed model prediction for MH and deep 
remission in VDZ-treated CD patients with endoscopically active disease at baseline.3 
Finally, we transformed this prediction model into a CDST for use in routine practice. This 
study is reported according to the Transparent Reporting of a multivariable prediction model 
for Individual Prognosis Or Diagnosis (TRIPOD) statement.9
Data Sources and Participants
We used two data sources to derive and validate the prediction model and CDST.1, 3 First, 
the GEMINI 2 trial was used to derive the CREM prediction model, and to derive the CDST. 
Second, data from the VICTORY consortium were used to externally validate the CREM 
prediction model, to assess the performance of the prediction model for predicting MH and 
deep remission, and to validate the CDST.
A subset of participants in GEMINI 2 (n=814) was used in the post hoc analysis. To mimic a 
treat-straight-through cohort design, patients were included if they received VDZ induction 
therapy and did not receive placebo during maintenance therapy, irrespective of Week 6 
response status (Supplementary Material).
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CD patients from the VICTORY consortium were included in the validation cohort (n=336) 
if they had: started VDZ therapy for clinically and/or endoscopically active CD, completed 
VDZ induction therapy, had a clinical or endoscopic assessment of disease activity after 
VDZ induction therapy, and had a minimum follow-up period of 26 weeks after VDZ 
initiation (Supplementary Material).
Outcomes and Definitions
The primary objective was to develop and validate a prediction model for CREM with VDZ 
in patients with active CD. Three definitions of CREM were used for this purpose: (1) 
CREM after 26 weeks of VDZ therapy; (2) CSF-REM after 26 weeks of VDZ for subjects 
receiving corticosteroid at baseline; and (3) sustained CREM during 52 weeks of VDZ, 
defined as 10 of 12 study visits from Week 10 to Week 52, including the final visit (Week 
52). Clinical disease activity and remission were assessed using the Crohn’s disease activity 
index (CDAI; CREM defined as CDAI ≤150) in GEMINI 2, and the physician global 
assessment (CREM defined as absence of all CD-related symptoms) in the VICTORY 
consortium.11
A secondary analysis was performed to assess the performance of the model for predicting 
MH and deep remission after 26 weeks of VDZ in endoscopically active CD patients. MH 
could only be assessed in the VICTORY consortium, and was defined as the absence of 
ulcers or erosions on ileocolonoscopy, or absence of findings of inflammation on cross-
sectional imaging in patients who could not be adequately assessed with ileocolonoscopy. 
Deep remission was defined as achieving both CREM and MH, and CSF-deep remission 
was defined as achieving both CSF-REM and MH (Supplementary Material).12
Statistical Analysis
Model Derivation—Individual multi-variable logistic regression prediction models were 
built in the GEMINI 2 derivation cohort for the outcomes of: CREM after 26 weeks of VDZ; 
CSF-REM after 26 weeks of VDZ; and sustained CREM during 52 weeks of VDZ therapy.
13–18
 From these three individual CREM prediction models, a set of variables were chosen 
for inclusion in a single final single prediction model based on: (1) being predictive in at 
least two of the three individual models; (2) review of the literature;19, 20 and/or (3) expert 
opinion of the author group. These models were transformed into a single final prediction 
model, as opposed to being individually validated externally, because it was felt that having 
3 separate models to predict separate outcomes with the same intervention (ie, VDZ) would 
lead to uncertainty in interpretation in clinical practice, potentially diverging predictions, and 
ultimately poor uptake of the CDST.
To build this single final prediction model, we weighted the coefficient of regression of each 
variable from each individual model by an estimation of the inverse variance for each 
coefficient estimate.21, 22 This approach does not take into account the clinical importance of 
each outcome from each individual model, or individual provider opinions that may 
influence treatment decisions. Therefore, a sensitivity analysis was performed using survey 
results from VICTORY consortium investigators on how each outcome should be weighted 
for the final single prediction model equation (Supplementary Material).
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Albumin and CRP were both retained in the final model and have been previously shown to 
be the strongest predictors of exposure-efficacy relationships for VDZ in CD.23 However, 
these 2 variables were observed to explain less than 30% of the variability in VDZ exposure. 
Therefore, a second sensitivity analysis was performed to more accurately account for 
variations in VDZ exposure by replacing baseline albumin and CRP with calculated VDZ 
clearance profiles within the GEMINI 2 derivation cohort. Calculated VDZ clearance for 
individual participants from the GEMINI 2 trial were obtained from previously published 
population pharmacokinetic-pharmacodynamics modeling and exposure-efficacy 
relationship studies.23, 24 A comparison of accuracy for predicting CREM, CSF-REM, and 
sustained CREM were then performed within the GEMINI 2 derivation cohort to determine 
if albumin and CRP should be replaced by the population pharmacokinetic-
pharmacodynamic model equation.
Model Validation—The final single prediction model was then validated externally in the 
VICTORY consortium cohort. Discriminative ability was assessed by receiver operating 
characteristic (ROC) curve analysis and is presented as AUC. The values are between 0.5 
and 1, with 0.5 denoting that the model does not discriminate and 1 denoting that it perfectly 
discriminates. Calibration was tested by the Hosmer–Lemeshow goodness-of-fit test after 
splitting the sample into quintiles. This test assesses whether or not the observed event rates 
match expected event rates in subgroups of the model population, with P-values <0.05 
indicating evidence of poor fit. The overall performance of the models was evaluated with 
the Nagelkerke R2 and the Brier score. Nagelkerke R2 is a measure between 0 and 1, with 0 
denoting that the model does not explain any variation and 1 denoting that it perfectly 
explains the observed variation. The Brier score is a measure between 0 and 1 of prediction 
with the mean squared difference between the predicted probability and the actual outcome. 
A lower Brier score indicates better performance, and the Brier score for a model can range 
from 0 for a perfect model to 0.25 for a non-informative model.25
Clinical Decision Support Tool—The final single prediction model was then 
transformed into a CDST, and prognostic scores were calculated for each patient.26 Cut-
points for a low, intermediate, and high probability of response were determined using the 
GEMINI 2 cohort. Stratifying GEMINI 2 participants based on response status derived these 
cut-points. The top 25% were considered high probability, bottom 25% considered low 
probability, and all others intermediate. These cut-points that differentiated the low, 
intermediate, and high probability groups were then applied to the GEMINI 2 intention-to-
treat population to understand how the probability of response with VDZ compared with 
placebo-treated participants. Finally, the CDST cut-points were applied to the VICTORY 
consortium, and the sensitivity, specificity, positive likelihood ratio (PLR), and negative 
likelihood ratio (NLR) of the scoring tool were calculated to identify patients with a low or 
high probability of responding to VDZ. (Supplementary Material)
Role of Sponsor
The protocol was designed by the study investigators in collaboration with scientists 
employed by Takeda Pharmaceuticals. All statistical analyses on the GEMINI 2 dataset were 
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performed by Takeda Pharmaceuticals employees. All statistical analyses on the VICTORY 
consortium dataset were performed by VICTORY consortium study investigators.
RESULTS
Patient Demographics
Of the 477 CD patients within the VICTORY consortium who were started on VDZ for 
clinically and/or endoscopically active disease, 104 patients were excluded for lacking 
baseline C-reactive protein (CRP) data within 4 weeks of initiation of VDZ therapy, and 
another 36 were excluded for having a follow-up of less than 26 weeks. Characteristics were 
similar between the entire VICTORY CD consortium cohort and the VICTORY CD 
consortium cohort selected for validation (Table 1). Baseline age, gender, and BMI were 
similar between the GEMINI and VICTORY cohorts. Patients in the GEMINI clinical trial 
had shorter disease duration (9 vs 14 years), and fewer patients had prior bowel surgeries (44 
vs 59%) or prior exposure to a TNFα-antagonist (66 vs 92%) (Table 1).
Model Derivation
The univariable models from the GEMINI 2 derivation cohort were used to derive separate 
models for CREM at Week 26, CSF-REM at Week 26, and sustained CREM 
(Supplementary Material). The absence of prior exposure to TNFα-antagonist therapy, 
absence of prior bowel surgery, absence of prior fistulizing disease, baseline albumin, and 
baseline CRP were included in the final single prediction model (Table 2). Weighted 7-day 
liquid or very soft stool score was identified as an independent predictor in all 3 individual 
models, but this was not included in the final single prediction model as the confidence 
interval closely approached or included 1.00 for estimates, and this variable was felt to be 
too subjective and therefore at risk for misclassification in routine practice.
Model Validation
The variables were fitted and re-run on the GEMINI 2 cohort to generate a final single 
weighted model equation (Supplementary Material):
Y = –3.0722 + [0.3483 if no prior TNFα-antagonist exposure] + [0.2305 if no prior bowel 
surgery] + [0.1979 if no prior fistulizing disease] + [0.0436 × baseline albumin in g/L] – 
[0.0098 × baseline CRP concentration in mg/L]
A sensitivity analysis was performed by weighting the model based on the VICTORY 
consortium investigator surveys (Supplementary Material):
Y = –3.2679 + [0.3048 if no prior TNFα-antagonist exposure] + [0.2299 if no prior bowel 
surgery] + [0.2452 if no prior fistulizing disease] + [0.0428 × baseline albumin in g/L] – 
[0.0108 × baseline CRP concentration in mg/L]
These equations were both externally validated on the VICTORY consortium cohort, and 
both demonstrated fair to good overall performance with no considerable differences 
between the 2 equations (Table 3, Supplementary Material).
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A sensitivity analysis was then performed by replacing albumin and CRP with calculated 
VDZ clearance profiles for GEMINI 2 participants based on population modeling and 
exposure-efficacy relationship assessments.23, 24 Performance of this model within the 
GEMINI 2 derivation cohort was comparable to the original model that included albumin 
and CRP (Supplementary Material).
The final single model equation used was therefore based on the 5 selected baseline 
variables weighted by an estimate of the inverse variance for each coefficient (Table 3).
Clinical Decision Support Tool
The final single model equation was transformed into a CDST and points were assigned to 
each variable based on multiplication of β coefficient by 10 and rounding to the nearest 
value. Non-linearity in distribution was observed for CRP and therefore it was transformed 
into a categorical value for the CDST, and an assessment of accuracy revealed that the 
modified CDST with CRP as a categorical value had higher sensitivity than the model with 
CRP as a continuous value (Supplementary Material and Table 4). The final CDST therefore 
had CRP as a categorical value (Figure 1).
Among the intention-to-treat population of GEMINI 2, the difference in CREM rates 
between VDZ and placebo at Week 6 was smaller in participants who would have been 
classified as low probability (≤13 points) for responding to VDZ (4.7% vs 2.8%; difference 
1.9%), compared with participants who would have classified as high probability (>19 
points) for responding to VDZ (23.9% vs 14.3%; difference 9.6%). Furthermore, among re-
randomized Week 6 responders, the difference in CREM rates at Week 52 between VDZ 
every 8 weeks and placebo was smaller between the low probability group (25.8% vs 3.6%; 
difference 22.2%) and the high probability group (61.7 vs 33.3%; difference 28.4%).
Patients in the VICTORY validation cohort were stratified into low (≤13 points), 
intermediate (>13 to ≤19 points), and high (>19 points) probability for responding to VDZ, 
with good discriminative performance for the CDST (Figure 1). A cut-off of 13 points had 
high sensitivity for identifying patients who were likely to respond to VDZ and a cut-off of 
19 points had a modest-high specificity for identifying patients who were likely to respond 
to VDZ (Table 4). Treatment outcomes among the VICTORY consortium patients in the low 
probability group were similar irrespective of number of prior TNFα-antagonists used, prior 
TNFα-antagonist failure versus intolerance, or concomitant immunosuppressive use (P>0.05 
for all comparisons).
Among the intermediate (>13 to ≤19 points) to high probability (>19 points) groups, rates of 
MH were significantly higher in patients with no prior fistulizing disease (83% vs. 68%, 
p=0.05), and trended towards significance for those with no prior surgery (55% vs. 39%, 
p=0.08). When stratified by CRP categories, patients with an intermediate to high 
probability score had lower rates of CREM (38.1% vs. 29.4% vs 20%, p=0.01), CSF-REM 
(32.4% vs 20.8% vs. 15.2%, p=0.08), and corticosteroid free deep remission (18% vs. 11.8% 
vs. 8.7%, p=0.32).
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DISCUSSION
Prior prediction models in CD have largely focused on estimating an individual patient’s 
probability of developing complications to help decide whether or not highly effective 
therapeutic approaches, such as early combined immunosuppression with a biologic, would 
be preferred strategies.27–30 However, prediction models for treatment outcomes with 
biologic therapy in CD are limited. Two clinical models have been built for predicting 
primary non-response to TNFα-antagonists; however, performance of these models was 
limited by inadequate precision due to low event rates and sample sizes, and lack of external 
validation.31, 32 Therefore, high-quality clinical prediction models to guide therapeutic 
decisions in CD are lacking. We derived and externally validated a multivariable prediction 
model that accurately predicts CREM, CSF-REM, MH, and deep remission with VDZ 
therapy in patients with CD. We further transformed this prediction model into an easy to 
use prognostic CDST, which demonstrated a good predictive value for identifying patients 
with either a low or high probability of responding to VDZ. Prospective use of the CDST is 
likely to improve the overall cost-effectiveness of biologic therapy in CD, by identifying 
patients who will most likely respond to VDZ and allow therapies to be selected 
accordingly. Furthermore, discussion of the results of the CDST with patients offers 
providers an opportunity to more readily engage in shared decision-making and 
personalization of treatment decisions.
Based on our model, the optimal positioning of VDZ within current treatment paradigms is 
prior to TNFα-antagonist exposure (supporting its use as a first-line biological agent), or 
early in the disease course prior to the development of disease-related complications (eg, 
fistulizing disease, bowel surgery). A risk score of ≤13 points had a very high sensitivity for 
identifying those less likely to respond to therapy, and a score of > 19 points had a modest 
specificity for identifying those more likely to respond to therapy. Among patients with an 
intermediate (>13 to ≤19 points) or high (>19 points) probability of response to VDZ, 
having an elevated baseline CRP (> 3 mg/L) was associated with lack of response to VDZ 
and was the predominant factor for misclassification in these groups. These observations 
could be due to several reasons including: an inherent resistance to responding to any 
biologic therapy in these refractory patients,33 alterations in immune phenotype with prior 
TNFα-antagonist exposure,34–36 or variations in pharmacokinetics and VDZ drug exposure.
23, 24
 To address the latter of these, we performed a sensitivity analysis by including 
individual participant VDZ clearance profiles based on population modeling, and observed 
no differences in model performance or accuracy for predicting outcomes. This would 
suggest that these variables are not simply surrogates for VDZ clearance and exposure but 
rather true prognostic markers of therapeutic response.
The strengths of this study include its size, scope, and external validation in an independent 
dataset. The derivation and validation of the data from multiple sites and jurisdictions, along 
with the simplicity of the CDST, enhances its generalizability and performance. In addition, 
the model is able to simultaneously predict outcomes of importance to patients (CREM and 
CSF-REM at 26 weeks) as well as outcomes associated with improved disease course (MH 
and deep remission) after initiation of VDZ, which are of importance to patients and 
physicians. Several limitations should be acknowledged. Firstly, these were post hoc 
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analyses of the GEMINI 2 clinical trial dataset, which was not powered for subgroup 
analyses and did not have endoscopic confirmation of efficacy outcomes. Caution should be 
taken when interpreting the differences in outcomes across subgroups and the results of the 
intention-to-treat population results stratified by probability of response. Secondly, although 
the prediction model had a favorable diagnostic accuracy, it explains less than 10% of the 
variability in outcomes. Prior work has demonstrated that the combination of serologic or 
genetic markers may help to improve the diagnostic accuracy of prediction models in CD.
29, 32
 Therefore, future studies are still needed to determine if biomarkers can be identified 
to help improve the accuracy of our clinical prediction model, as well as its ability to explain 
variability in outcomes with VDZ. Thirdly, the model had a poor fit when validated in the 
VICTORY consortium. The poor fit of the model may be due in part to the variability in 
outcome definitions, known risk of disease activity classification in CD with symptom based 
indices, or the combining of several models into a single model for ease of clinical 
interpretation and integration. Although the model exhibited poor calibration for matching 
predictive and observed probabilities throughout the whole range of potential prognostic 
estimates, the CDST demonstrated a high sensitivity for identifying those at risk for 
treatment failure. This highlights that predictive models and CDSTs are simply one piece of 
a multi-step process that includes physician assessments and patient preferences, to choose 
the most appropriate therapies and optimize treatment effectiveness on an individualized 
basis in routine practice. Future studies are needed to better calibrate the model and assess 
the impact of this prediction model and CDST on clinical practice, health care resource 
utilization, and treatment outcomes, when implemented at the population level.
In summary, we have derived and externally validated a clinical prediction model for 
treatment outcomes with VDZ, with good overall performance and accuracy. We have 
further transformed this prediction model into an easy to use CDST to help guide patients 
and providers on the appropriate positioning of VDZ within current treatment algorithms. 
Based on our model the ideal positioning of VDZ may be early in the disease course prior to 
exposure to TNF-antagonists and prior to the development of CD related complications. 
Further studies are needed to determine how our prediction model can be used to optimize 
treatment outcomes at the population level.
Supplementary Material
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CDST clinical decision support tool
CI confidence interval
CREM clinical remission
CRP C-reactive protein
CSF-REM corticosteroid-free remission
MH mucosal healing
NLR negative likelihood ratio
PLR positive likelihood ratio
ROC receiver operating characteristic
TNFα tumor necrosis factor-alpha
VDZ vedolizumab
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Figure 1. 
Prognostic Clinical Decision Support Tool with stratified treatment outcomes in VICTORY 
consortium. CD, Crohn’s disease; CRP, C-reactive protein; CREM, clinical remission; CSF-
REM, corticosteroid-free remission; ds, disease; MH, mucosal healing; CSF-Deep 
Remission, corticosteroid-free deep remission; TNF, tumor necrosis factor; VDZ, 
vedolizumab.
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Table 1.
Comparison of Demographics Between GEMINI 2 and VICTORY Consortium Cohorts
GEMINI 2 VICTORY consortium
Overall
cohort
(n=814)
Overall
cohort
(n=477)
Validation
cohort
(n=336)
Female sex, n (%) 435 (53) 279 (58) 192 (57)
Mean age, years (SD) 35.5 (11.9) 39.3 (15.4) 38.1 (15.1)
Mean BMI, kg/m2 (SD) 24.0 (6.0) 25.4 (6.8) 25.5 (6.9)
Mean disease duration, years (SD) 9.1 (7.5) 14.4 (11) 14.1 (10.6)
Concomitant CS only, n (%) 280 (34) 133 (28) 96 (28)
Concomitant IMMs only, n (%) 133 (16) 90 (19) 66 (20)
Concomitant CS and IMMs, n (%) 137 (17) 105 (22) 75 (22)
Prior TNFα antagonist exposure, n (%) 535 (66) 441 (92) 309 (92)
Prior TNFα antagonist failure, n (%) 497 (61) 374 (78) 263 (78)
Median CRP, mg/L (IQR) 10.6 (4.5–31.6) − 5.0 (1.0–19.4)
Mean albumin, g/L (SD) 34.9 (5.7) − 38.2 (5.7)
Disease localization, n (%)*
 Ileum only
 Colon only
 Ileocolonic
141 (17)
230 (28)
443 (54)
78 (16)
108 (23)
291 (61)
48 (14)
76 (23)
212 (63)
Prior surgery for CD, n (%) 355 (44) 287 (60) 199 (59)
Prior fistulizing disease, n (%) 297 (36) 183 (38) 136 (40)
*As per patient history at the time of enrolment into GEMINI 2 or the initiation of vedolizumab therapy in the VICTORY consortium.
BMI, body mass index; CD, Crohn’s disease; CRP, C-reactive protein; CS, corticosteroid; IMM, immunomodulator; SD, standard deviation; TNFα, 
tumor necrosis factor-alpha.
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Table 2.
Multivariable Analyses for Remission in the GEMINI 2 Derivation Cohort
Independent Predictor* OR† Confidence Interval
Clinical Remission
 No prior CD related hospitalization* 1.43 1.08,1.89
 No baseline EIM 1.43 1.09, 1.88
 No previous bowel surgery 1.49 1.12,1.98
 No previous TNFα antagonist 2.18 1.65, 2.88
 Baseline CRP 0.99 0.98, 1.00
 Ethnicity (Other vs. Non-hispanic/Latino) 0.30 0.12, 0.75
 Weighted 7-day liquid or very soft stool 0.99 0.99, 1.00
 Baseline Albumin 1.04 1.01,1.08
Corticosteroid-Free Remission
 No history of fistulizing disease 1.85 1.13, 3.03
 No previous TNFα antagonist 1.80 1.16, 2.80
 Baseline CRP 0.98 0.97, 1.00
 Weighted 7-day liquid or very soft stool 0.99 0.99, 1.00
Sustained Clinical Remission
 No history of fistulizing disease 1.82 1.22, 2.71
 No previous bowel surgery 1.71 1.18, 2.49
 No previous TNFα antagonist 1.42 1.01, 2.00
 Baseline Albumin 1.07 1.04,1.10
 Weighted 7-day liquid or very soft stool 0.995 0.99, 1.00
*CD-related hospitalization within the previous 12 months.
CRP, C-reactive protein; OR, odds ratio; TNFα, tumor necrosis factor-alpha.
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Table 3.
Performance of Final Single Prediction Model in VICTORY Consortium Validation Cohort
Clinical
remission
26 weeks
Corticosteroid-
free remission
26 weeks*
Mucosal
healing
26 weeks
Deep
Remission
26 weeks
Corticosteroid-
free Deep
Remission
26 weeks*
Nagelkerke R2 0.06 0.06 0.07 0.06 0.07
Brier score 0.24 0.18 0.16 0.11 0.09
ROC-AUC
(95% CI)
0.67
(0.63, 0.73)
0.66
(0.57, 0.76)
0.72
(0.64, 0.80)
0.73
(0.64, 0.81)
0.75
(0.64, 0.86)
Hosmer–Lemeshow goodness-of-fit test: The model-exhibited poor fit (P<0.05) for all outcomes.
*
Performed for subset of patients who were on corticosteroids at baseline.
Final single prediction model based on inverse variance weighting and includes: no prior bowel surgery, no prior TNFα-antagonist exposure, no 
history of fistulizing disease, baseline albumin, and baseline CRP score. Nagelkerke R-squared is a measure between 0 and 1, with 0 denoting that 
model does not explain any variation and 1 denoting that it perfectly explains the observed variation. The Brier score is a measure between 0 and 1 
of prediction with the mean squared difference between the predicted probability and the actual outcome. The Brier score for a model can range 
from 0 for a perfect model to 0.25 for a non-informative model. ROC-AUC curve values are between 0.5 and 1, with 0.5 denoting that the model 
does not discriminate and 1 denoting that it perfectly discriminates. In the Hosmer–Lemeshow goodness-of-fit test, observed event rates are tested 
against expected event rates by decile of fitted values for prediction; P-values <0.05 indicate evidence of poor fit.
AUC, area under the curve; CD, Crohn’s disease; CRP, C-reactive protein; ROC, receiver operating characteristic; CI: confidence interval.
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Table 4.
Diagnostic Accuracy of Prognostic Clinical Decision Support Tool for Identifying Patients Likely to Respond 
to Vedolizumab using CRP as categorical value
Sensitivity
(95% CI)
Specificity
(95% CI)
PLR
(95% CI)
NLR
(95% CI)
13 points
 Clinical remission after 26 weeks 92%(85–97%)
25%
(20–31%)
1.24
(1.12–1.36)
0.30
(0.14–0.64)
 Corticosteroid-free remission after 26 weeks*
94%
(81–99%)
30%
(22–38%)
1.34
(1.17–1.54)
0.19
(0.05–0.76)
 Mucosal healing after 26 weeks 98%(88–100%)
30%
(23–37%)
1.39
(1.25–1.54)
0.08
(0.01–0.55)
 Deep Remission after 26 weeks 100%(88–100%)
28%
(22–35%)
1.39
(1.28–1.51)
0.00
(−)
 Corticosteroid-Free Deep Remission after 26 weeks*
100%
(75–100%)
31%
(23–41%)
1.45
(1.28–1.65)
0.00
(−)
19 points
 Clinical remission after 26 weeks 33%(24–44%)
80%
(74–85%)
1.65
(1.12–2.42)
0.84
(0.72–0.98)
 Corticosteroid-free remission after 26 weeks*
37%
(22–55%)
77%
(69–84%)
1.62
(0.95–2.75)
0.82
(0.62–1.07)
 Mucosal healing after 26 weeks 40%(25–56%)
80%
(74–86%)
2.01
(1.26–3.20)
0.75
(0.59–0.97)
 Deep Remission after 26 weeks 38%(21–58%)
79%
(73–84%)
1.78
(1.05–3.04)
0.79
(0.59–1.06)
 Corticosteroid-Free Deep Remission after 26 weeks*
46%
(19–75%)
78%
(69–85%)
2.07
(1.05–4.09)
0.69
(0.42–1.16)
*
Performed for subset of patients who were on corticosteroids at baseline. Stratified analysis by baseline steroid dose performed with no significant 
changes in performance.
PLR, positive likelihood ratio; NLR, negative likelihood ratio.
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